Selected Grants
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Bicara Therapeutics Inc. · 2025 - 2030A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCIN
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2024 - 2029InnovaTV207 SGNTV 001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. SGNTV001
Clinical TrialPrincipal Investigator · Awarded by Seagen, Inc · 2024 - 2029Basket study of MK-4280A in select solid tumors (MK4280A-010)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2028Time restricted eating to improve immunotherapy outcomes in African American patients with Head and Neck cancer.
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Foundation · 2024 - 2026External Relationships
- Exelixis, Inc.
- FLX/ RAPT Biotherapeutics
- Oncominds Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.